BOTHELL, Wash.--(BUSINESS WIRE)--June 22, 2006--Seattle Genetics, Inc. (NASDAQ:SGEN - News) announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration agreement with CuraGen Corporation (NASDAQ:CRGN - News), triggering an undisclosed payment to Seattle Genetics. The milestone was achieved upon CuraGen’s initiation of a phase I clinical trial with its lead ADC, CR011-vcMMAE, for the treatment of metastatic melanoma.
